DDR1

Incendia Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 38th Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Society for Immunotherapy of Cancer, Prevalence, DDR1, Doctor of Philosophy, Translational medicine, SITC, Immunotherapy, Disease, Neoplasm, Annual general meeting, Tumor microenvironment, Society, Therapy, TME, Prognosis, Medical imaging, Cholangiocarcinoma

Incendia Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that it will present three posters at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held in San Diego, California November 1-5, 2023.

Key Points: 
  • Incendia Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that it will present three posters at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held in San Diego, California November 1-5, 2023.
  • “We look forward to presenting three posters at SITC which validate our approach to block Discoidin Domain Receptor 1 (DDR1) and advance our understanding of and ability to detect immune exclusion in solid tumors,” said Laura Dillon, PhD, VP, Translational Medicine & Bioinformatics at Incendia Therapeutics.
  • “We are encouraged by the human tumor data in intrahepatic cholangiocarcinoma (iCCA), which demonstrate a correlation of high DDR1 expression with worse prognosis in all stages of disease.
  • The prevalence of high DDR1 expression and poor survival outcomes associated with this make iCCA a relevant tumor type for evaluating novel DDR1-targeted therapies.”
    Presentation Details for SITC 2023 are as follows:

 Incendia Therapeutics Announces Upcoming Presentations at the European Society for Medical Oncology Congress 2023

Retrieved on: 
Monday, October 16, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Congress, Cancer, TME, Tumor microenvironment, DDR1, ESMO, Therapy, Mesenchyme, European Society for Medical Oncology, Neoplasm, Translational medicine, Pharmaceutical industry, Medical imaging

Incendia Therapeutics , formerly Parthenon Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that it will have two poster presentations at the European Society for Medical Oncology (ESMO) Congress 2023, to be held in Madrid, Spain October 20-24, 2023.

Key Points: 
  • Incendia Therapeutics , formerly Parthenon Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that it will have two poster presentations at the European Society for Medical Oncology (ESMO) Congress 2023, to be held in Madrid, Spain October 20-24, 2023.
  • A high proportion of tumor cells (median of 0.76) expressed DDR1 across all epithelial tumor types.
  • DDR1 expression was uniformly low in mesenchymal tumors (median of 9 cells/mm2) compared to epithelial tumors (median of 2803 cells/mm2).
  • The third part (Ph1c) consists of dose expansion in disease-directed cohorts to assess the anti-tumor efficacy of PRTH-101 monotherapy and/or combination therapy.

Parthenon Therapeutics Announces Publication in Journal for ImmunoTherapy of Cancer on the Role of PRTH-101 Inhibiting DDR1 in Immune Excluded Tumors

Retrieved on: 
Thursday, June 22, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, Neoplasm, DDR1, Parthenon, JITC, Journal, MD, University, TME, Mab, Collagen, ECM, Therapy, Immunotherapy, George Washington University, Tumor microenvironment, Breast cancer, Pharmaceutical industry, Cancer

Parthenon Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that the Journal for ImmunoTherapy of Cancer (JITC) has published results from a collaboration between Parthenon Therapeutics, The University of Texas Health Center at Houston (UTHealth Houston) and George Washington University, demonstrating that PRTH-101 potently inhibits the adhesion of collagen receptor discoid in domain receptor-1 (DDR1)-expressing cancer cells to collagen substrates and DDR1 autophosphorylation induced by collagen.

Key Points: 
  • Parthenon Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that the Journal for ImmunoTherapy of Cancer (JITC) has published results from a collaboration between Parthenon Therapeutics, The University of Texas Health Center at Houston (UTHealth Houston) and George Washington University, demonstrating that PRTH-101 potently inhibits the adhesion of collagen receptor discoid in domain receptor-1 (DDR1)-expressing cancer cells to collagen substrates and DDR1 autophosphorylation induced by collagen.
  • The article entitled, “A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer,” describes the humanization of PRTH-101 and the mechanism by which the drug candidate binds to its target to inhibit DDR1.
  • The publication is now available online on the JITC website .
  • “This study reinforces the development of PRTH-101 as a cancer therapeutic, and also sheds light on a new therapeutic strategy to modulate collagen alignment in the tumor ECM for enhancing antitumor immunity.”

Parthenon Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor for the Treatment of Immune-Excluded Solid Tumors

Retrieved on: 
Tuesday, April 25, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, DDR1, Cancer, Neoplasm, FDA, Therapy, MD, Tumor microenvironment, Patient, Parthenon, TME, Medical imaging

Parthenon Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that the first patient has been dosed with PRTH-101 in a Phase 1, first-in-human clinical trial for patients with immune-excluded solid tumors.

Key Points: 
  • Parthenon Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that the first patient has been dosed with PRTH-101 in a Phase 1, first-in-human clinical trial for patients with immune-excluded solid tumors.
  • PRTH-101 is a first-in-class Discoidin Domain Receptor 1 (DDR1) antagonist monoclonal antibody that is expressed at very high levels in solid tumors with low levels of T cell infiltration.
  • PRTH-101 is the first development candidate from Parthenon’s broad TME-focused pipeline to enter clinical development.
  • PRTH-101 uniquely targets DDR1 and has demonstrated, in preclinical models, anti-tumor activity as a single agent and in combination with an anti-PD-1 checkpoint inhibitor.

Parthenon Therapeutics Announces Data at the American Association for Cancer Research (AACR) Annual Meeting 2023 on Prevalence of Immune Exclusion in Solid Tumors to Support Phase 1 Clinical Trial of PRTH-101

Retrieved on: 
Monday, April 17, 2023
Oncology, Health, FDA, Clinical Trials, Research, Science, AACR, Prevalence, DDR1, Clinical trial, Clinical research, Cancer, Multimedia, Lung cancer, Doctor of Philosophy, Parthenon, Incidence, Sarcoma, Translational medicine, Patient, Colorectal cancer, TME, Immunohistochemistry, American Association for Cancer Research, Therapy, Ovarian cancer, Tumor microenvironment, Pharmaceutical industry, Vaccine, MD

The data further support Parthenon’s planned Phase 1 clinical trial of lead candidate PRTH-101, a novel Discoidin Domain Receptor (DDR1) inhibitor which targets DDR1-directed collagen barriers in immune excluded tumors.

Key Points: 
  • The data further support Parthenon’s planned Phase 1 clinical trial of lead candidate PRTH-101, a novel Discoidin Domain Receptor (DDR1) inhibitor which targets DDR1-directed collagen barriers in immune excluded tumors.
  • However, most patients with solid tumors lack immune cells in physical proximity to tumor cells.
  • This can be due to collagen barriers that prevent immune cells from reaching tumor cells in immune excluded tumors.
  • The poster detailing these findings - #2108 - will be presented at the American Association of Cancer Research (AACR) Annual Meeting on Monday, April 17, 2023.

Parthenon Therapeutics Showcases New Precision Oncology Technology Designed to Breakdown Barriers in Immune-excluded Tumors

Retrieved on: 
Wednesday, November 16, 2022
General Health, Health, Clinical Trials, Health Technology, Oncology, Trial of the century, DDR1, Neoplasm, Drug development, Therapy, TME, Discoidin domain, Conference, Cancer, Precision medicine, Parthenon, Tumor microenvironment, Patient, Pharmaceutical industry, Medical imaging

Parthenon Therapeutics, a precision oncology company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME), today unveiled its precision medicine approach to address cancers with hight unmet need, at the Stifel Healthcare Conference.

Key Points: 
  • Parthenon Therapeutics, a precision oncology company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME), today unveiled its precision medicine approach to address cancers with hight unmet need, at the Stifel Healthcare Conference.
  • We are delighted to showcase our pipeline and technology to the scientific community and anticipate that we will pioneer a new approach to treating patients with immune-excluded tumors.
  • Our data have shown over 50% of solid tumors are immune-excluded, indicating a significant unmet need for these patients, said Laurent Audoly, co-founder and Chief Executive Officer of Parthenon Therapeutics.
  • Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME).

Parthenon Therapeutics and ImaginAb Announce License and Supply Agreement to Advance New Class of Anti-Cancer Therapies’ Clinical Development Program

Retrieved on: 
Thursday, November 10, 2022
Research, Clinical Trials, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Tumor microenvironment, Collagen, PET, Immunotherapy, Health, RPT, Neoplasm, Technology, CD8, DDR1, Therapy, Doctor of Philosophy, Cancer, Phenotype, Biomarker, Drug development, Clinical trial, Cell, Patient, Immune system, TME, Data, Phase II, Pharmaceutical industry, Medical imaging, Parthenon

This knowledge will help us design a clinical strategy to focus on those patients who will benefit the most from treatment with PRTH-101.

Key Points: 
  • This knowledge will help us design a clinical strategy to focus on those patients who will benefit the most from treatment with PRTH-101.
  • Under the terms of the agreement, ImaginAb will supply clinical doses of its investigational CD8 ImmunoPET technology to Parthenon Therapeutics for use in the clinical development of PRTH-101 at clinical trial sites across the United States.
  • ImaginAb is actively investing in the clinical and global supply chain development of CD8 ImmunoPET agent to provide simple turnkey access to its novel technology for use in clinical research and development.
  • Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME).

Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis

Retrieved on: 
Monday, May 16, 2022
Epithelium, DDR1, Fibroblast, Private Securities Litigation Reform Act, Food, Survival, U.S. Securities and Exchange Commission, Patient, NASDAQ, ROCK2, CYP11B2, Prescription, COVID-19, PDGF, Cell, Kidney, FDA, IND, DDR2, Plasma, Fibrosis, Safety, Pathology, Degenerative disease, Lung, Therapy, Security (finance), Idiopathic pulmonary fibrosis, IPF, PK, Arm, Investigational New Drug, GLOBE, Pharmaceutical industry, Vaccine

UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced U.S. Food and Drug Administration’s (FDA) acceptance of an Investigational New Drug (IND) application supporting the clinical development of ANG-3070 in idiopathic pulmonary fibrosis (IPF) and clearance to begin a Phase 1b study of ANG-3070 in patients with IPF.

Key Points: 
  • IPF patients eligible for this Phase 1b study of ANG-3070 include those who have discontinued nintedanib or pirfenidone, refused treatment with nintedanib or pirfenidone, or those who are treatment nave.
  • Approximately 20 IPF patients will be enrolled into a crossover design trial with four arms dosing for ten days each.
  • A Phase 1b trial of ANG-3070 in patients with idiopathic pulmonary fibrosis is targeted to enroll and report data in 2022.
  • A Phase 1b trial of ANG-3070 in patients with idiopathic pulmonary fibrosis is targeted to enroll and report data in 2022.

Alliance Memory Cuts Lead Times for DRAMs and Micron NOR Flash Memory Products With Automotive Temperature Ratings

Retrieved on: 
Thursday, December 2, 2021
CMOS, DDR2, Micron Technology, Temperature, LPDDR4X, AEC, 4MBS, SDRAM, ICS, Micrometre, DDR1, SRAM, NOR, GLOBE, Parallel, SDR, ADAS, 4GB Music Festival, DRAM, 2GB, Dram, Carputer, Computer data storage, Engineered wood

KIRKLAND, Wash., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Alliance Memory today announced that it has greatly reduced lead times for its DRAMs and Micron Technology NOR Flash memory devices with automotive temperature ratings.

Key Points: 
  • KIRKLAND, Wash., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Alliance Memory today announced that it has greatly reduced lead times for its DRAMs and Micron Technology NOR Flash memory devices with automotive temperature ratings.
  • Responding to customer demand, the company now holds 70 parts in finished goods stock and can provide lead times of just six weeks for its most popular automotive temperature range products.
  • Alliance Memory offers a complete lineup of CMOS SDRAMs including DDR1, DDR2, DDR3/L, LPDDR4, and LPDDR4X devices with automotive temperature ratings of -40C to +105C.
  • Alliance Memory is a worldwide provider of critical and hard-to-find memory ICs for the communications, computing, consumer electronics, medical, automotive, and industrial markets.

Parthenon Therapeutics Raises $65 Million in Series A Funding to Advance Oncology Programs Aimed at Reprogramming the Tumor Microenvironment

Retrieved on: 
Wednesday, November 3, 2021
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Drug discovery, Cancer, DDR1, Research, Molecular medicine, LinkedIn, University of Texas System, Manuscript, George Washington University, Neoplasm, Outline of health sciences, Drug development, Survival, Parthenon, MBA, TME, Section 32, Secondary research, Patient, School, Investment, George Washington University School of Medicine & Health Sciences, TNBC, Medicine, ECM, University, Chief medical officer, Biochemistry, Laboratory, Coronavirus Scientific Advisory Board (Turkey), Therapy, Tumor microenvironment, Department, Pharmaceutical industry

Parthenon Therapeutics, a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment, today announced a $65 million Series A financing led by Northpond Ventures, Pfizer Ventures, and Taiho Ventures.

Key Points: 
  • Parthenon Therapeutics, a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment, today announced a $65 million Series A financing led by Northpond Ventures, Pfizer Ventures, and Taiho Ventures.
  • The company plans to use the funds to develop new therapies that target immune exclusion in tumors.
  • This novel approach leverages unique molecular insights into the function of DDR1 to develop a fit-for-purpose therapeutic approach.
  • Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME).